37 citations · 75 across the 30 of their papers we have counts for
8 papers · 1 filter
Backfilling Cohorts in Phase I Dose-Escalation Studies
Helen Barnett, Oliver Boix, Dimitris Kontos +1
The use of `backfilling', assigning additional patients to doses deemed safe, in phase I dose-escalation studies has been used in practice to collect additional information on the…
Dose Finding Studies for Therapies with Late-Onset Safety and Efficacy Outcomes
Helen Barnett, Oliver Boix, Dimitris Kontos +1
In Phase I/II dose-finding trials, the objective is to find the Optimal Biological Dose (OBD), a dose that is both safe and efficacious that maximises some optimality criterion bas…
Dose Finding Studies for Therapies with Late-Onset Toxicities: A Comparison Study of Designs
Helen Barnett, Oliver Boix, Dimintris Kontos +1
An objective of phase I dose-finding trials is to find the maximum tolerated dose; the dose with a particular risk of toxicity. Frequently, this risk is assessed across the first c…
A Seamless Phase I/II Platform Design with a Time-To-Event Efficacy Endpoint for Potential COVID-19 Therapies
Thomas Jaki, Helen Barnett, Andrew Titman +1
In the search for effective treatments for COVID-19, initial emphasis has been on re-purposed treatments. To maximise the chances of finding successful treatments, novel treatments…
Adding experimental treatment arms to Multi-Arm Multi-Stage platform trials in progress
Thomas Burnett, Franz König, Thomas Jaki
Multi-Arm Multi-Stage (MAMS) platform trials are an efficient tool for the comparison of several treatments. Suppose we wish to add a treatment to a trial already in progress, to a…
Adding flexibility to clinical trial designs: an example-based guide to the practical use of adaptive designs
Thomas Burnett, Pavel Mozgunov, Philip Pallmann +3
Adaptive designs for clinical trials permit alterations to a study in response to accumulating data in order to make trials more flexible, ethical and efficient. These benefits are…